Introduction
Carcinoid tumours are uncommon neoplasms with a reported incidence of 1.5 per 100 000 population. Although they can develop in any organ derived from primitive endoderm, they occur most frequently in the appendix. Primary carcinoid tumours can be classified according to their site of origin. Although this classification into fore-gut, mid-gut or hind-gut tumours is of no prognostic significance, it is of clinical value in that the classical features of malignant carcinoid syndrome are much more likely in metastatic disease originating from a mid-gut primary tumour. These features, which include cutaneous flushing, diarrhoea and bronchospasm, result from the secretory products of this neuroendocrine tumour which include 5-hydroxytryptamine, kallikrein, tachykinins, substance P, prostaglandins and catecholamines.',' Carcinoid tumours of fore-gut origin tend to have different neuro-endocrine products, secreting histamine and 5-hydroxytryptophan.
5-Hydroxytryptamine (5-HT) is the cause of carcinoid diarrhoea and flushing may be related to either prostaglandin or tachykinin production. 3 Patients with malignant carcinoid syndrome have a remarkably good prognosis even though the majority have liver metastases at presentation. Moertel reported a median survival of 38 months with a range extending to 15 years. 4 In the Hammersmith Hospital series of 68 patients, 48% survived 5 2. Peripheral 5-HT antagonists Cyproheptadine, ketanserin, methysergide and ondansetron are included within this group of agents. Cyproheptadine at a dose of 4 mg thrice daily led to an improvement in flushing in 47% and of diarrhoea in 60% ofpatients. The mean duration ofsymptom response was 8 months and side effects were minimal.3 Ketanserin is known to cause specific blockade of 5-HT2 receptors as well as HI and alpha adrenoceptors. It controls flushing in about 50% of patients but only one fifth find relief from diarrhoea.
3. Antihistamines and other agents Combined HI and H2 blockade using chlorpheniramine and cimetidine may be used in cases presenting atypically with urticarial skin rashes occurring in association with foregut primary carcinoids. When catecholamine synthesis is suspected the use of phenoxybenzamine may produce useful relief of symptoms. Aprotinin inhibits kinin production, and may sometimes be effective.
Inhibitors ofS-HTrelease
Many clinicians now consider somatostatin analogues to be the treatment of first choice for patients with carcinoid syndrome. Somatostatin has been termed an 'endocrine bleach', inhibiting the release of neuropeptides and gut endocrine and exocrine function. It also inhibits other functions of the gut, decreasing mobility, absorption and blood flow. Early studies showed a reduction in symptoms caused by carcinoid lesions with treatment with octreotide, a long acting analogue of somatostatin.'4 This long acting analogue has the advantage over the native hormone ofa prolonged plasma half life of 90-120 minutes with a duration of action of 6-8 hours. The prolonged action of this octapeptide results from the presence of two Damino acids, which resist degradation by endogenous peptidases. Initial relief of symptoms has been reported in up to 80% of patients.'4 The same study showed a nadir of 5-HIAA excretion at 1 month, with a median response duration of 12 months. Patients are taught to administer octreotide themselves and the only side effect is a slight discomfort at the injection site. There have been no reports of renal, hepatic, central nervous system or other toxicity, and the treatment is well tolerated. It is now known that with its prolonged use increasing dosages are required to maintain symptom control.
Somatostatin analogues are also used in the management of acute carcinoid crisis precipitated by surgery or radiological intervention, when ensuing cardiovascular instability can be rapidly reversed by intravenous administration of octreotide.'" Discussion Symptom control in metastatic carcinoid syndrome is ofprime importance in view of the lack of effective treatment to reduce tumour bulk. The most effective therapy for this condition is somatostatin analogue treatment. It may be that new approaches using this compound in combination with biological response modifying agents such as the interferons may provide an advantage in terms of reduction in tumour volume as well as symptom relief. These studies are currently in progress.
